Moleculin Announces its Sponsored Research at MD Anderson Cancer Center Has Resulted in the Filing of Patent Protection for New Discovery
HOUSTON, Sept. 16, 2019 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced its sponsored research at MD...
Moleculin Biotech, Inc. Reports Financial Results for the Second Quarter Ended June 30, 2019
HOUSTON, Aug. 16, 2019 -- Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced its financial results for the second...
Moleculin Announces Completion of Lymphoma Trial Enrollment
HOUSTON, Aug. 13, 2019 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced its proof of concept clinical trial...
Moleculin Announces Breakthrough Discovery: WP1066 Potentially Capable of Immune Reprogramming in Glioblastoma Animal Models
Data to be presented at the Inaugural Conference on Brain Metastases, August 16-17, 2019HOUSTON, Aug. 6, 2019 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates...
Moleculin Announces Annamycin in Acute Myeloid Leukemia in Poland Advances to 3rd Cohort
HOUSTON, July 18, 2019 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced additional positive interim safety...
Moleculin Files for New Patents for Annamycin After Receiving FDA Approval of Fast Track Designation
HOUSTON, July 10, 2019 -- Moleculin Biotech, Inc. (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced it has filed new patents covering the...
Moleculin Biotech, Inc. Reports Financial Results for the First Quarter Ended March 31, 2019
HOUSTON, May 14, 2019 -- Moleculin Biotech, Inc. (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced its financial results for the first...
Moleculin Announces Additional Positive Interim Results in First Cohort of Phase 1/2 Clinical Studies of Annamycin in Acute Myeloid Leukemia in Europe
2 of 3 patients qualify to proceed to a potentially curative bone marrow transplant; trial advances to next higher dose levelHOUSTON, May 7, 2019 -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a...
US Biopharma Company Undertakes Anti-Cancer Clinical Trials in Poland, First Patient Showing Positive Initial Treatment
Moleculin quickly recruited qualified patients and started trials for two of its portfolio drugs to supplement US efforts.HOUSTON, April 29, 2019 -- A small public company with 6 highly promising anti-cancer drugs in the pipeline is augmenting US clinical trials with...
Moleculin Announces $15.0 Million Registered Direct Offering
HOUSTON, April 23, 2019 -- Moleculin Biotech, Inc., (NASDAQ: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced that it has entered into definitive...